Publicaciones en las que colabora con Susana Roselló (20)

2024

  1. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients

    Translational Research, Vol. 271, pp. 105-115

2023

  1. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 8

  2. The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer

    Colorectal Disease, Vol. 25, Núm. 6, pp. 1135-1143

2021

  1. Circulating tumor dna detection by digital-droplet pcr in pancreatic ductal adenocarcinoma: A systematic review

    Cancers, Vol. 13, Núm. 5, pp. 1-14

  2. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

    British Journal of Cancer, Vol. 125, Núm. 9, pp. 1261-1269

2020

  1. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: Oncological outcomes at a single academic centre

    ESMO Open, Vol. 5, Núm. 6

2019

  1. Assessing molecular subtypes of gastric cancer: Microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications

    ESMO Open, Vol. 4, Núm. 3

  2. Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens

    Histopathology, Vol. 75, Núm. 4, pp. 517-525

  3. Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression

    Modern Pathology, Vol. 32, Núm. 2, pp. 306-313

  4. Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

    Diseases of the Colon and Rectum, Vol. 62, Núm. 6, pp. 684-693

2018

  1. Borderline resectable pancreatic cancer. Challenges and controversies

    Cancer Treatment Reviews, Vol. 68, pp. 124-135

  2. Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. 104-112.e2

  3. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

    Cancer Chemotherapy and Pharmacology, Vol. 82, Núm. 6, pp. 935-943

2016

  1. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

    Oncotarget, Vol. 7, Núm. 16, pp. 22543-22555

  2. Epigenetic changes in localized gastric cancer: The role of RUNX3 in tumor progression and the immune microenvironment

    Oncotarget, Vol. 7, Núm. 39, pp. 63424-63436

2015

  1. Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer

    Oncotarget, Vol. 6, Núm. 29, pp. 26935-26945

2014

  1. Implicaciones pronósticas del estudio estandarizado de los márgenes de resección en el cáncer de páncreas

    Cirugia Espanola, Vol. 92, Núm. 8, pp. 532-538

2011

  1. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

    Cancer, Vol. 117, Núm. 14, pp. 3118-3125

2010

  1. The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment

    Clinical and Translational Oncology, Vol. 12, Núm. 5, pp. 339-345

2008

  1. Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: Perioperative management of rectal cancer

    Annals of Oncology